The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Diagnosis, management, and treatment of hepatitis C†
Abstract
HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HIV, human immunodeficiency virus; anti-HCV, HCV antibody; RNA, ribonucleic acid; PCR, polymerase chain reaction; TMA, transcription-mediated amplification; FDA, Food and Drug Administration; HCC, hepatocellular carcinoma; SVR, sustained virologic response; EVR, early virologic response; ETR, end of treatment response; peginterferon, pegylated interferon; G-CSF, granulocyte colony-stimulating factor; HAART, highly active antiretroviral therapy; ddI, didanosine; GM-CSF, granulocyte-macrophage colony-stimulating factor. These recommendations provide a data-supported approach. They are based on the following: (1) a formal review and analysis of the recently published world literature on the topic (Medline search); (2) the American College of Physicians' Manual for Assessing Health Practices and Designing Practice Guidelines1 ; (3) guideline policies, including the American Association for the Study of Liver Diseases' (AASLD) Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association's Policy Statement on the Use of Medical Practice Guidelines2; the guideline procedures of the Infectious Diseases Society of America3; and (4) the experience of the authors in the specified topic. These recommendations are fully endorsed by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology. Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic and preventive aspects of care. They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. In an attempt to characterize the quality of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a category to be assigned and reported with each recommendation (Table 1). The hepatitis C virus (HCV) is a major public health problem and a leading cause of chronic liver disease. In the United States, the Centers for Disease Control and Prevention estimates that there are more than 2.7 million people with ongoing HCV infection.5 HCV is the leading cause of death from liver disease in the United States.6 The purpose of this article is to provide clinicians with approaches to the diagnosis, management, and prevention of HCV infection. The optimal methods of detecting HCV infection are to screen populations for history of risk and to test selected individuals with an identifiable risk factor. With careful questioning, an HCV risk factor can be identified in more than 90% of cases.7 The primary source of HCV transmission is HCV-infected blood or blood products. In the United States, injection drug use is the chief mode of transmission, and anyone who has ever injected illicit drugs should be tested.5, 7 Persons should also be tested if they received a blood or blood component transfusion or organ transplant before 1992, when sensitive tests were first used to screen donors for HCV antibodies. Since that time, HCV infection is rarely transmitted by transfusion.8 Other potential sources of HCV transmission include exposure to an infected sexual partner or multiple sexual partners, frequent exposure to infected blood among health care workers, and perinatal exposure.9-11 Although HCV prevalence rates are consistently higher in persons with multiple sexual partners, sexual transmission of HCV between monogamous partners is rare.7 Thus, while it is common to counsel HCV-infected persons to notify their current partners of their HCV status, they should be told that the risk of sexual transmission is sufficiently low12 that many authorities do not advise use of barrier precautions (i.e., latex condoms). Testing of sexual partners, therefore, is done chiefly for reassurance. There is no need to curtail ordinary household activities except those that might result in blood exposure, such as sharing a razor or toothbrush. HCV is not transmitted by hugging and the sharing of eating utensils. Although a monogamous sexual relationship carries a low risk of transmission of HCV infection, as noted above, the risk is higher in persons involved with multiple sexual partners. Persons with hemophilia should be tested for HCV infection if blood products were received before 1987, when viral inactivation procedures were implemented. It is also advisable to test persons for HCV infection if they have evidence of otherwise unexplained elevations of aminotransferase levels (alanine and/or aspartate aminotransferases; ALT /AST), have ever been on hemodialysis, or have human immunodeficiency virus (HIV) infection.10 Other situations that have been suggested to carry a risk for HCV transmission include certain folk medicine practices (acupuncture, ritual scarification), body piercing, tattooing, and even commercial bar
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Centers for Disease Control and Prevention
(2007) · Encyclopedia of Measurement and Statistics · doi:10.4135/9781412952644.n74 · Cited by 6,444
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C., & Smith, A. D. (2009) · Hepatology · doi:10.1002/hep.22742 · Cited by 1,997
The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., & Alter, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00004 · Cited by 1,955
Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis
Friedrich–Rust, M., Ong, M., Martens, S., Sarrazin, C., Bojunga, J., Zeuzem, S., & Herrmann, E. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.034 · Cited by 1,490
EASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.023 · Cited by 1,088
Lin, Z.-H., Xin, Y.-N., Dong, Q.-J., Wang, Q., Jiang, X.-J., Zhan, S.-H., Sun, Y., & Xuan, S.-Y. (2011) · Hepatology · doi:10.1002/hep.24105 · Cited by 1,067
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
Mangia, A., Santoro, R., Minerva, N., Ricci, G. L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042608 · Cited by 840
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma
Arzumanyan, A., Reis, H. M. G. P. V., & Feitelson, M. A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3449 · Cited by 800
Barber, R. M., Fullman, N., Sorensen, R. J. D., Bollyky, T., McKee, M., Nolte, E., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30818-8 · Cited by 764
Platt, L., Easterbrook, P., Gower, E., McDonald, B., Sabin, K., McGowan, C., Yanny, I., Razavi, H., & Vickerman, P. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00485-5 · Cited by 731
Coco, B., Oliveri, F., Maina, A. M., Ciccorossi, P., Sacco, R., Colombatto, P., Bonino, F., & Brunetto, M. R. (2007) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00811.x · Cited by 662
Interferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients
D'Amico, G., Pasta, L., Morabito, A., D'Amico, M., Caltagirone, M., Malizia, G., Tinè, F., Giannuoli, G., Traina, M., Vizzini, G., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12721 · Cited by 547
Moucari, R., Asselah, T., Cazals–Hatem, D., Voitot, H., Boyer, N., Ripault, M., Sobesky, R., Martinot–Peignoux, M., Maylin, S., Nicolas–Chanoine, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.010 · Cited by 546
Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection
Adams, L. A., Bulsara, M., Rossi, E., DeBoer, B., Speers, D., George, J., Kench, J., Farrell, G., McCaughan, G. W., & Jeffrey, G. P. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.048389 · Cited by 539
Tolman, K. G., Fonseca, V., Dalpiaz, A., & Tan, M. H. (2007) · Diabetes Care · doi:10.2337/dc06-1539 · Cited by 525
Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
Shiffman, M. L., Suter, F., Bacon, B. R., Nelson, D., Harley, H., Solá, R., Shafran, S. D., Barange, K., Lin, A., Soman, A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066403 · Cited by 493
Rosen, H. R. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1006613 · Cited by 487
Peginterferon and Ribavirin for Chronic Hepatitis C
Hoofnagle, J. H., & Seeff, L. B. (2006) · New England Journal of Medicine · doi:10.1056/nejmct061675 · Cited by 476
Self-citationFriedrich‐Rust, M., Nierhoff, J., Lupsor, M., Sporea, I., Fierbinteanu‐Braticevici, C., Strobel, D., Takahashi, H., Yoneda, M., Suda, T., Zeuzem, S., et al. (2012) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2011.01537.x · Cited by 475
Conjeevaram, H. S., Fried, M. W., Jeffers, L. J., Terrault, N. A., Wiley–Lucas, T. E., Afdhal, N., Brown, R. S., Belle, S. H., Hoofnagle, J. H., Kleiner, D. E., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.06.008 · Cited by 472
Masuzaki, R., Tateishi, R., Yoshida, H., Goto, E., Sato, T., Ohki, T., Imamura, J., Goto, T., Kanai, F., Kato, N., et al. (2009) · Hepatology · doi:10.1002/hep.22870 · Cited by 435
Natural History of Hepatitis C
Thomas, D. L., & Seeff, L. B. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2005.05.003 · Cited by 402
Self-citationShaheen, A. A. M., & Myers, R. P. (2007) · Hepatology · doi:10.1002/hep.21835 · Cited by 397
Hepatitis C virus infection protein network
de Chassey, B., Navratil, V, Tafforeau, L., Hiet, M. S., Aublin‐Gex, A., Agaugué, S., Meiffren, G., Pradezynski, F., Faria, B. F., Chantier, T., et al. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.66 · Cited by 384
Perni, R. B., Almquist, S. J., Byrn, R. A., Chandorkar, G., Chaturvedi, P. R., Courtney, L. F., Decker, C. J., Dinehart, K., Gates, C. A., Harbeson, S. L., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.899-909.2006 · Cited by 386
Castéra, L., Bail, B. L., Roudot-Thoraval, F., Bernard, P.-H., Foucher, J., Merrouche, W., Couzigou, P., & de Lédinghen, V. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.08.018 · Cited by 384
Huwart, L., Sempoux, C., Salameh, N., Jamart, J., Annet, L., Sinkus, R., Peeters, F., ter Beek, L. C., Horsmans, Y., & Van Beers, B. E. (2007) · Radiology · doi:10.1148/radiol.2452061673 · Cited by 365
Singal, A. G., Volk, M. L., Jensen, D., Di Bisceglie, A. M., & Schoenfeld, P. S. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.11.018 · Cited by 362
Shaheen, A. A. M., Wan, A. F., & Myers, R. P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01466.x · Cited by 360
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy†
Everson, G. T., Trotter, J., Forman, L., Kugelmas, M., Halprin, A., Fey, B., & Ray, C. (2005) · Hepatology · doi:10.1002/hep.20793 · Cited by 357
Lackner, C., Struber, G., Liegl, B., Leibl, S., Ofner, P., Bankuti, C., Bauer, B., & Stauber, R. E. (2005) · Hepatology · doi:10.1002/hep.20717 · Cited by 340
Heterogeneity of liver cancer and personalized therapy
Li, L., & Wang, H. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.07.018 · Cited by 339
Swain, M. G., Lai, M., Shiffman, M. L., Cooksley, W. G. E., Zeuzem, S., Dieterich, D. T., Abergel, A., Pessôa, M. G., Lin, A., Tietz, A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.009 · Cited by 328
Limited Uptake of Hepatitis C Treatment Among Injection Drug Users
Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D., Vlahov, D., Strathdee, S. A., & Thomas, D. L. (2008) · Journal of Community Health · doi:10.1007/s10900-007-9083-3 · Cited by 327
Self-citationTreatment predictors of a sustained virologic response in hepatitis B and C
Kau, A., Vermehren, J., & Sarrazin, C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.013 · Cited by 324
Koh, C., Li, Q., & Liang, J. (2016) · Clinical Virology · doi:10.1128/9781555819439.ch54 · Cited by 321
Nosocomial infections in patients with cancer
Kamboj, M., & Sepkowitz, K. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70069-5 · Cited by 318
Susser, S., Welsch, C., Wang, Y., Zettler, M., Domingues, F. S., Karey, U., Hughes, E., Ralston, R., Tong, X., Herrmann, E., et al. (2009) · Hepatology · doi:10.1002/hep.23192 · Cited by 318
The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease
Lim, Y.-S., & Kim, W. R. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.007 · Cited by 316
Viral hepatitis and HIV coinfection
Sulkowski, M. S. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.009 · Cited by 316
Rein, D. B., Smith, B. D., Wittenborn, J. S., Lesesne, S. B., Wagner, L. D., Roblin, D. W., Patel, N., Ward, J. W., & Weinbaum, C. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-4-201202210-00378 · Cited by 302
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C†
Huang, H., Shiffman, M. L., Friedman, S., Venkatesh, R., Bzowej, N., Abar, O. T., Rowland, C. M., Catanese, J. J., Leong, D. U., Sninsky, J. J., et al. (2007) · Hepatology · doi:10.1002/hep.21695 · Cited by 297
Self-citationCalvaruso, V., Burroughs, A. K., Standish, R., Manousou, P., Grillo, F., Leandro, G., Maimone, S., Pleguezuelo, M., Xirouchakis, I., Piero Guerrini, G., et al. (2009) · Hepatology · doi:10.1002/hep.22745 · Cited by 289
Exceeding the limits of liver histology markers
Mehta, S. H., Lau, B., Afdhal, N. H., & Thomas, D. L. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.039 · Cited by 273
Self-citationNon invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy
Sebastiani, G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i23.3682 · Cited by 266
A Systematic Review of the Quality of Liver Biopsy Specimens
Cholongitas, E., Senzolo, M., Standish, R., Marelli, L., Quaglia, A., Patch, D., Dhillon, A. P., & Burroughs, A. K. (2006) · American Journal of Clinical Pathology · doi:10.1309/w3xc-nt4h-kfbn-2g0b · Cited by 264
Sebastiani, G., Vario, A., Guido, M., Noventa, F., Plebani, M., Pistis, R., Ferrari, A., & Alberti, A. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.01.007 · Cited by 263
Ramasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., Rodin, G., Schaffer, A., Beaulieu, S., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400110 · Cited by 206
Codes, L., Asselah, T., Cazals-Hatem, D., Tubach, F., Vidaud, D., Paraná, R., Bedossa, P., Valla, D., & Marcellin, P. (2007) · Gut · doi:10.1136/gut.2006.101931 · Cited by 137
Psychiatric and Substance Use Disorders in Individuals with Hepatitis C: Epidemiology and Management
Loftis, J. M., Matthews, A. M., & Hauser, P. (2006) · Drugs · doi:10.2165/00003495-200666020-00003 · Cited by 86
Murakami, Y., Ishibashi, T., Tomita, E., Imamura, Y., Tashiro, T., Watcharanurak, K., Nishikawa, M., Takahashi, Y., Takakura, Y., Mitani, S., et al. (2016) · Scientific Reports · doi:10.1038/srep29920 · Cited by 52
Freedman, K., & Nathanson, J. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.1 · Cited by 16
Baliashvili, D., Blumberg, H. M., Gandhi, N. R., Averhoff, F., Benkeser, D., Shadaker, S., Gvinjilia, L., Turdziladze, A., Tukvadze, N., Chincharauli, M., et al. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1004121
Metadata
- Authors
- Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B.
- Venue
- Hepatology
- Published
- 2004-04
- Volume
- 39
- Issue
- 4
- Pages
- 1147-1171
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2047208492
- Cited by
- 1,709
- References
- 135
- FWCI
- 99.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.